{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:54:49Z","timestamp":1793145289463,"version":"4.5.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"am","delay-in-days":306,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K08482"],"award-info":[{"award-number":["22K08482"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.intimp.2024.112612","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T22:43:59Z","timestamp":1720046639000},"page":"112612","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Trastuzumab, a monoclonal anti-HER2 antibody modulates cytotoxicity against cholangiocarcinoma via multiple mechanisms"],"prefix":"10.1016","volume":"138","author":[{"given":"Jutatip","family":"Panaampon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8078-275X","authenticated-orcid":false,"given":"Prin","family":"Sungwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sawako","family":"Fujikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7783-6103","authenticated-orcid":false,"given":"Somponnat","family":"Sampattavanich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwanon","family":"Jirawatnotai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3124-5206","authenticated-orcid":false,"given":"Seiji","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.intimp.2024.112612_b0005","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","article-title":"Cholangiocarcinoma - evolving concepts and therapeutic strategies","volume":"15","author":"Rizvi","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112612_b0010","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2020.03.008","article-title":"Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma","volume":"73","author":"Montal","year":"2020","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112612_b0015","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","article-title":"Cholangiocarcinoma","volume":"7","author":"Brindley","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"6","key":"10.1016\/j.intimp.2024.112612_b0020","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/ng.2273","article-title":"Exome sequencing of liver fluke-associated cholangiocarcinoma","volume":"44","author":"Ong","year":"2012","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/j.intimp.2024.112612_b0025","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/MOG.0000000000000162","article-title":"Genetics of Opisthorchis viverrini-related cholangiocarcinoma","volume":"31","author":"Jusakul","year":"2015","journal-title":"Curr. Opin. Gastroenterol."},{"issue":"10","key":"10.1016\/j.intimp.2024.112612_b0030","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.intimp.2024.112612_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.actatropica.2021.106133","article-title":"Current status of human liver fluke infections in the Greater Mekong Subregion","volume":"224","author":"Sripa","year":"2021","journal-title":"Acta Trop."},{"issue":"4758","key":"10.1016\/j.intimp.2024.112612_b0040","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1126\/science.3012781","article-title":"The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity","volume":"232","author":"Akiyama","year":"1986","journal-title":"Science"},{"issue":"19","key":"10.1016\/j.intimp.2024.112612_b0045","doi-asserted-by":"crossref","first-page":"6497","DOI":"10.1073\/pnas.82.19.6497","article-title":"A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1\/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma","volume":"82","author":"Semba","year":"1985","journal-title":"PNAS"},{"issue":"4717","key":"10.1016\/j.intimp.2024.112612_b0050","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.2992089","article-title":"Amplification of a novel v-erbB-related gene in a human mammary carcinoma","volume":"229","author":"King","year":"1985","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.intimp.2024.112612_b0055","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1001\/jamaoncol.2015.2286","article-title":"The Evolving Landscape of HER2 Targeting in Breast Cancer","volume":"1","author":"Moasser","year":"2015","journal-title":"JAMA Oncol."},{"issue":"4785","key":"10.1016\/j.intimp.2024.112612_b0060","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"issue":"34","key":"10.1016\/j.intimp.2024.112612_b0065","doi-asserted-by":"crossref","first-page":"5700","DOI":"10.1200\/JCO.2009.23.2025","article-title":"High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller","volume":"27","author":"Gonzalez-Angulo","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112612_b0070","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab\u2013mechanism of action and use in clinical practice","volume":"357","author":"Hudis","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.112612_b0075","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40364-024-00565-1","article-title":"HER2-targeted therapies in cancer: a systematic review","volume":"12","author":"Zhu","year":"2024","journal-title":"Biomark Res"},{"issue":"3","key":"10.1016\/j.intimp.2024.112612_b0080","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s13577-020-00334-w","article-title":"Functional and genetic characterization of three cell lines derived from a single tumor of an Opisthorchis viverrini-associated cholangiocarcinoma patient","volume":"33","author":"Sripa","year":"2020","journal-title":"Hum. Cell"},{"issue":"5","key":"10.1016\/j.intimp.2024.112612_b0085","doi-asserted-by":"crossref","DOI":"10.3390\/cells8050496","article-title":"Establishment of Highly Transplantable Cholangiocarcinoma Cell Lines from a Patient-Derived Xenograft Mouse Model","volume":"8","author":"Vaeteewoottacharn","year":"2019","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.intimp.2024.112612_b0090","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1007\/s12185-013-1339-3","article-title":"Establishment of a CD4-positive cell line from an AIDS-related primary effusion lymphoma","volume":"97","author":"Goto","year":"2013","journal-title":"Int. J. Hematol."},{"issue":"9","key":"10.1016\/j.intimp.2024.112612_b0095","doi-asserted-by":"crossref","first-page":"e02490","DOI":"10.1016\/j.heliyon.2019.e02490","article-title":"Ephedrine enhances HIV-1 reactivation from latency through elevating tumor necrosis factor receptor II (TNFRII) expression","volume":"5","author":"Panaampon","year":"2019","journal-title":"Heliyon"},{"issue":"5","key":"10.1016\/j.intimp.2024.112612_b0100","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s00262-021-03054-8","article-title":"Efficacy and mechanism of the anti-CD38 monoclonal antibody Daratumumab against primary effusion lymphoma","volume":"71","author":"Panaampon","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"issue":"10","key":"10.1016\/j.intimp.2024.112612_b0105","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1007\/s00262-022-03177-6","article-title":"Elotuzumab, a potential therapeutic humanized anti-SLAMF7 monoclonal antibody, enhances natural killer cell-mediated killing of primary effusion lymphoma cells","volume":"71","author":"Panaampon","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"issue":"10","key":"10.1016\/j.intimp.2024.112612_b0110","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1016\/j.ejca.2014.03.004","article-title":"Efficacy of anti-CD47 antibody-mediated phagocytosis with macrophages against primary effusion lymphoma","volume":"50","author":"Goto","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.intimp.2024.112612_b0115","article-title":"Comparative study of human hematopoietic cell engraftment into BALB\/c and C57BL\/6 strain of rag-2\/jak3 double-deficient mice","volume":"2011","author":"Ono","year":"2011","journal-title":"J. Biomed. Biotechnol."},{"issue":"3","key":"10.1016\/j.intimp.2024.112612_b0120","doi-asserted-by":"crossref","first-page":"310","DOI":"10.4161\/mabs.19873","article-title":"Development and validation of an antibody-dependent cell-mediated cytotoxicity-reporter gene assay","volume":"4","author":"Parekh","year":"2012","journal-title":"Mabs"},{"issue":"10","key":"10.1016\/j.intimp.2024.112612_b0125","doi-asserted-by":"crossref","first-page":"e1486948","DOI":"10.1080\/2162402X.2018.1486948","article-title":"Daratumumab induces CD38 internalization and impairs myeloma cell adhesion","volume":"7","author":"Ghose","year":"2018","journal-title":"Oncoimmunology"},{"issue":"6","key":"10.1016\/j.intimp.2024.112612_b0130","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1158\/1078-0432.CCR-15-2095","article-title":"The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia","volume":"23","author":"Matas-Cespedes","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.intimp.2024.112612_b0135","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00280-006-0337-z","article-title":"Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models","volume":"59","author":"Fujimoto-Ouchi","year":"2007","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"12","key":"10.1016\/j.intimp.2024.112612_b0140","doi-asserted-by":"crossref","first-page":"e0226593","DOI":"10.1371\/journal.pone.0226593","article-title":"Binding and functional profiling of antibody mutants guides selection of optimal candidates as antibody drug conjugates","volume":"14","author":"Zwaagstra","year":"2019","journal-title":"PLoS One"},{"issue":"46","key":"10.1016\/j.intimp.2024.112612_b0145","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.18632\/oncotarget.27815","article-title":"Identification of Mubritinib (TAK 165) as an inhibitor of KSHV driven primary effusion lymphoma via disruption of mitochondrial OXPHOS metabolism","volume":"11","author":"Calderon","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.intimp.2024.112612_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.103997","article-title":"A review of HER2 overexpression and somatic mutations in cancers","volume":"186","author":"Galogre","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112612_b0155","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10555-015-9552-6","article-title":"HER2 expression status in diverse cancers: review of results from 37,992 patients","volume":"34","author":"Yan","year":"2015","journal-title":"Cancer Metastasis Rev."},{"issue":"5","key":"10.1016\/j.intimp.2024.112612_b0160","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1002\/hep.30704","article-title":"Dependency of Cholangiocarcinoma on Cyclin D-Dependent Kinase Activity","volume":"70","author":"Sittithumcharee","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.intimp.2024.112612_b0165","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1038\/ncomms5378","article-title":"The Opisthorchis viverrini genome provides insights into life in the bile duct","volume":"5","author":"Young","year":"2014","journal-title":"Nat. Commun."},{"issue":"6924","key":"10.1016\/j.intimp.2024.112612_b0170","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nature01392","article-title":"Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab","volume":"421","author":"Cho","year":"2003","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.intimp.2024.112612_b0175","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1093\/annonc\/mdl475","article-title":"Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer","volume":"18","author":"Valabrega","year":"2007","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.intimp.2024.112612_b0180","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/bcr1612","article-title":"HER2 therapy: molecular mechanisms of trastuzumab resistance","volume":"8","author":"Nahta","year":"2006","journal-title":"Breast Cancer Res."},{"issue":"2","key":"10.1016\/j.intimp.2024.112612_b0185","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/sj.bjc.6602930","article-title":"Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?","volume":"94","author":"Arnould","year":"2006","journal-title":"Br. J. Cancer"},{"issue":"26","key":"10.1016\/j.intimp.2024.112612_b0190","doi-asserted-by":"crossref","first-page":"23441","DOI":"10.1074\/jbc.M300848200","article-title":"The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition","volume":"278","author":"Le","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.intimp.2024.112612_b0195","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1158\/0008-5472.CAN-03-3106","article-title":"Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects","volume":"64","author":"Jackson","year":"2004","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.intimp.2024.112612_b0200","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1158\/1535-7163.MCT-09-1171","article-title":"Activated phosphoinositide 3-kinase\/AKT signaling confers resistance to trastuzumab but not lapatinib","volume":"9","author":"O'Brien","year":"2010","journal-title":"Mol Cancer Ther"},{"issue":"14","key":"10.1016\/j.intimp.2024.112612_b0205","first-page":"4132","article-title":"Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action","volume":"62","author":"Yakes","year":"2002","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.intimp.2024.112612_b0210","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2005.00.661","article-title":"Neoadjuvant trastuzumab induces apoptosis in primary breast cancers","volume":"23","author":"Mohsin","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.intimp.2024.112612_b0215","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat. Med."},{"issue":"17","key":"10.1016\/j.intimp.2024.112612_b0220","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.1158\/1078-0432.CCR-04-0225","article-title":"Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2","volume":"10","author":"Gennari","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2024.112612_b0225","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/1479-5876-11-307","article-title":"Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2\/neu breast cancer patients","volume":"11","author":"Petricevic","year":"2013","journal-title":"J. Transl. Med."},{"issue":"24","key":"10.1016\/j.intimp.2024.112612_b0230","doi-asserted-by":"crossref","first-page":"11991","DOI":"10.1158\/0008-5472.CAN-07-2068","article-title":"Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2","volume":"67","author":"Varchetta","year":"2007","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.intimp.2024.112612_b0235","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1093\/annonc\/mdr484","article-title":"Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines","volume":"23","author":"Collins","year":"2012","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.intimp.2024.112612_b0240","doi-asserted-by":"crossref","first-page":"4379","DOI":"10.4049\/jimmunol.1402891","article-title":"Trastuzumab triggers phagocytic killing of high HER2 cancer cells in vitro and in vivo by interaction with Fcgamma receptors on macrophages","volume":"194","author":"Shi","year":"2015","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2024.112612_b0245","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.155636","article-title":"Trastuzumab\/pertuzumab combination therapy stimulates antitumor responses through complement-dependent cytotoxicity and phagocytosis","volume":"7","author":"Tsao","year":"2022","journal-title":"JCI Insight"},{"issue":"24","key":"10.1016\/j.intimp.2024.112612_b0250","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.131882","article-title":"CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis","volume":"4","author":"Tsao","year":"2019","journal-title":"JCI Insight"},{"issue":"4","key":"10.1016\/j.intimp.2024.112612_b0255","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/ijc.30500","article-title":"Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients","volume":"140","author":"Bhusari","year":"2017","journal-title":"Int. J. Cancer"},{"issue":"29","key":"10.1016\/j.intimp.2024.112612_b0260","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2026849118","article-title":"Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance","volume":"118","author":"Upton","year":"2021","journal-title":"PNAS"},{"issue":"5","key":"10.1016\/j.intimp.2024.112612_b0265","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/j.1349-7006.2002.tb01293.x","article-title":"Enhanced anti-tumor effect of trastuzumab in combination with cisplatin","volume":"93","author":"Naruse","year":"2002","journal-title":"Jpn. J. Cancer Res."},{"key":"10.1016\/j.intimp.2024.112612_b0270","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.breast.2021.07.019","article-title":"Dissecting the biological heterogeneity of HER2-positive breast cancer","volume":"59","author":"Schettini","year":"2021","journal-title":"Breast"},{"issue":"2","key":"10.1016\/j.intimp.2024.112612_b0275","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/bcr3621","article-title":"Trastuzumab emtansine: mechanisms of action and drug resistance","volume":"16","author":"Barok","year":"2014","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.intimp.2024.112612_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104305","article-title":"Efficacy and safety of trastuzumab deruxtecan in treating human epidermal growth factor receptor 2-low\/positive advanced breast cancer: A meta-analysis of randomized controlled trials","volume":"196","author":"Ma","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"4","key":"10.1016\/j.intimp.2024.112612_b0285","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16040800","article-title":"Next-Generation HER2-Targeted Antibody-Drug Conjugates in Breast Cancer","volume":"16","author":"Zimmerman","year":"2024","journal-title":"Cancers (basel)"},{"key":"10.1016\/j.intimp.2024.112612_b0290","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.breast.2022.10.016","article-title":"Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer","volume":"66","author":"Rassy","year":"2022","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.intimp.2024.112612_b0295","doi-asserted-by":"crossref","first-page":"208","DOI":"10.37349\/etat.2024.00213","article-title":"Recent preclinical and clinical advances in radioimmunotherapy for non-Hodgkin's lymphoma","volume":"5","author":"Goto","year":"2024","journal-title":"Explor Target Antitumor Ther"},{"issue":"5","key":"10.1016\/j.intimp.2024.112612_b0300","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s00259-020-05094-1","article-title":"HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging","volume":"48","author":"Altunay","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"6","key":"10.1016\/j.intimp.2024.112612_b0305","first-page":"1523","volume":"151","author":"Petit","year":"1997","journal-title":"Am. J. Pathol."},{"issue":"13","key":"10.1016\/j.intimp.2024.112612_b0310","first-page":"5090","article-title":"Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis","volume":"61","author":"Viloria-Petit","year":"2001","journal-title":"Cancer Res."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924011330?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924011330?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:55:21Z","timestamp":1730854521000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924011330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":62,"alternative-id":["S1567576924011330"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112612","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trastuzumab, a monoclonal anti-HER2 antibody modulates cytotoxicity against cholangiocarcinoma via multiple mechanisms","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112612","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112612"}}